Δ9-Tetrahydrocannabivarin Beneficial in Type 2 Diabetes

Share this content:
&Delta;<sup>9</sup>-Tetrahydrocannabivarin Beneficial in Type 2 Diabetes
Δ9-Tetrahydrocannabivarin Beneficial in Type 2 Diabetes

THURSDAY, Sept. 1, 2016 (HealthDay News) -- For patients with non-insulin-treated type 2 diabetes, Δ9-tetrahydrocannabivarin (THCV) reduces fasting plasma glucose, and improves pancreatic β-cell function, adiponectin, and apolipoprotein A, according to a study published online Aug. 29 in Diabetes Care.

Khalid A. Jadoon, from the University of Nottingham in the United Kingdom, and colleagues conducted a randomized study involving 62 individuals with non-insulin-treated type 2 diabetes to examine the effects of cannabidiol (CBD) and THCV.

The researchers found that THCV correlated with a significant decrease in fasting plasma glucose compared with placebo, and with improved pancreatic β-cell function, adiponectin, and apolipoprotein A; plasma high-density lipoprotein was unaffected. CBD correlated with decreased resistin and increased glucose-dependent insulinotropic peptide compared with baseline (but not placebo). No significant impact was seen on end points for the combination treatments (CBD + THCV). Both CBD and THCV were well tolerated.

"THCV could represent a new therapeutic agent in glycemic control in subjects with type 2 diabetes," the authors write.

One author disclosed financial ties to GW Pharmaceuticals; GW Research Ltd. funded the study.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

USPSTF Urges Abuse Screening for Reproductive-Aged Women

USPSTF Urges Abuse Screening for Reproductive-Aged Women

Evidence lacking for assessing balance of benefits, harms of screening for abuse of seniors, vulnerable

Five-Day Nitrofurantoin Beats Single-Dose Fosfomycin for UTI

Five-Day Nitrofurantoin Beats Single-Dose Fosfomycin for UTI

Increased likelihood of clinical and microbiological resolution for uncomplicated UTI in women

Exercise Intervention Doesn't Improve Walking Ability in PAD

Exercise Intervention Doesn't Improve Walking Ability in PAD

Smaller mean change from baseline to follow-up in 6-minute walking distance with exercise intervention

is free, fast, and customized just for you!

Already a member?

Sign In Now »